Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices

2017 ◽  
Vol 34 (5) ◽  
Author(s):  
Maurice Herring ◽  
Lynn Huynh ◽  
Mei Sheng Duh ◽  
Francis Vekeman ◽  
Audrey Tiew ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Neuroendocrine Tumors ◽  
Real World ◽  
Treatment Patterns ◽  
Pancreatic Neuroendocrine Tumors ◽  
Community Oncology ◽  
Tertiary Center

Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis

Oncology ◽  
2018 ◽  
Vol 94 (5) ◽  
pp. 281-288 ◽  
Author(s):  
Michael S. Broder ◽  
Beilei Cai ◽  
Eunice Chang ◽  
Maureen P. Neary ◽  
Elya Papoyan ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Real World ◽  
Treatment Patterns ◽  
Database Analysis ◽  
Claims Database

scholarly journals Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

2020 ◽  
Author(s):  
Junji Lin ◽  
Lynn McRoy ◽  
Maxine D Fisher ◽  
Nan Hu ◽  
Cralen Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Medical Records ◽  
Metastatic Breast ◽  
Patient Characteristics ◽  
Treatment Patterns ◽  
Community Oncology ◽  
Label Indication ◽  
Free Rate

Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Materials & methods: Eligible patients receiving palbociclib-based therapy per label indication from 3 February 2015 to 31 December 2017 were included. Descriptive analyses were conducted for patient characteristics, treatment patterns and clinical outcomes. Results: The study included 233 patients who received palbociclib + aromatase inhibitor (P+AI) and 48 who received palbociclib + fulvestrant (P+F). Real-world progression-free rate for P+AI was 69.8% (46.8%) at 12 (24) months (P+F: 43.5% [39.9%]) months. Real-world survival rate was 89.8% (71.4%) at 12 (24) months (P+F: 76.3% [65.0%]). Conclusion: The study findings are consistent with previous studies of palbociclib-based therapy.

MM-079: Real-World Treatment Patterns and Outcomes of Triple-Exposed Multiple Myeloma (MM) Patients Treated in Community Oncology Practices in the US

2021 ◽  
Vol 21 ◽  
pp. S419-S420
Author(s):  
Robert Smith ◽  
Mei Xue ◽  
Natalie Dorrow ◽  
Prateesh Varughese ◽  
Cosmina Hogea ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Treatment Patterns ◽  
Community Oncology ◽  
The Us
Sign in / Sign up

Export Citation Format

Share Document